MECLIZINE HYDROCHLORIDE

Post-LOE

meclizine

Aurobindo Pharma

ANDAORALTABLET

Approved

Sep 2012

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

MECLIZINE HYDROCHLORIDE (meclizine) by Aurobindo Pharma is h1 receptor. Approved for vertigo associated with diseases affecting the vestibular system in adults (). First approved in 2012.

Drug data last refreshed 19h ago

Mechanism of Action

H1 receptor.

Indications (1)

vertigo associated with diseases affecting the vestibular system in adults ()

Clinical Trials (1)

NCT02112578Phase 3Completed

Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin

Started Nov 2016

292 enrolled

Vertigo, Peripheral

Company

Worked on MECLIZINE HYDROCHLORIDE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.